Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMJ8ACF)

Drug Name
ALX-0761 Drug Info
Indication
Disease Entry ICD 11 Status REF
Psoriasis vulgaris EA90 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMJ8ACF

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-17 (IL17) TTG0MT6 IL17_HUMAN Modulator [2]
Interleukin-25 (IL25) TTVMO5W IL25_HUMAN Modulator [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Interleukin-17 (IL17) DTT IL17A 5.188 3.828 3.329 4.615
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Psoriasis vulgaris
ICD Disease Classification EA90
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin-17 (IL17) DTT IL17A 2.91E-02 -0.16 -0.69
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT02156466) Multiple Ascending Dose Trial of MSB0010841 (Anti-IL17A/F Nanobody) in Psoriasis Subjects
2 Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.